Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Jasper Therapeutics announced it raised $132 Million in an initial filing from an offering of $132 Million
PUBLIC · JSPRAug 05, 2026•5 days ago
Amount Raised
$132 Million
Round Type
Venture - Series Unknown
Redwood CityBiotechnologyHealth CareTherapeutics
Company Information
Company
Jasper Therapeutics
Location
Redwood City, California, United States
About
Our mission is to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, safer and more effective conditioning for monogenetic diseases and new engineered stem cell therapies. Briquilimab (formerly JSP191) is a targeted anti c-Kit monoclonal antibody designed to deplete diseased mast and stem cells as well as enable safer and more effective curative hematopoietic stem cell transplants and stem cell gene therapies.
Related People
Suggested for you
3 contacts
Verified contactsMark, Vice President of IT and Facilities at… hidden
Predictive Intelligence
Strategic
ML-powered predictions for Jasper Therapeutics's next move
Redwood CityBiotechnologyHealth CareTherapeutics